Ibrutinib and atrial fibrillation: An in-depth review of clinical implications and management strategies

doi:10.4330/wjc.v16.i5.269

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1105)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

HTML

680

Figures (1-1)

129

Sum=838

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=121

May 26, 2024 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Cardiol. May 26, 2024; 16(5): 269-273
Published online May 26, 2024. doi: 10.4330/wjc.v16.i5.269

Ibrutinib and atrial fibrillation: An in-depth review of clinical implications and management strategies

Moiud Mohyeldin, Shitij Shrivastava, Sai Vishnu Vardhan Allu

Moiud Mohyeldin, Internal Medicine, University of Medical Sciences and Technology, Khartoum 11111, Sudan

Shitij Shrivastava, Sai Vishnu Vardhan Allu, Internal Medicine, Bronxcare Health System, Bronx, NY 10457, United States

Author contributions: Mohyeldin M contributed to conceptualization, methodology, visualization, supervision, and project administration; Mohyeldin M takes responsibility for the integrity of the work as a whole, from inception to published article; Mohyeldin M, Shrivastava S and Allu SVV contributed to investigation, writing - original draft, and writing - review & editing; Shrivastava S and Allu SVV contributed to resources; All authors have read and approved the final version of the manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Moiud Mohyeldin, MD, Doctor, Staff Physician, Internal Medicine, University of Medical Sciences and Technology, Khartoum, Khartoum 11111, Sudan. moiudahmed@gmail.com

Received: February 21, 2024
Revised: April 23, 2024
Accepted: May 14, 2024
Published online: May 26, 2024
Processing time: 91 Days and 16.1 Hours

Core Tip

Core Tip: This review examines the association between ibrutinib, a Bruton’s tyrosine kinase inhibitor, and atrial fibrillation (AF). It explores the underlying mechanisms, clinical implications, and management strategies for AF in patients treated with ibrutinib. The article emphasizes the need for cardiovascular monitoring and alternative treatments to balance therapeutic efficacy and safety.